allogeneic CD8+ PR3-specific CTLs

Developed for: acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute promyelocytic leukemia · blast phase chronic myelogenous leukemia, BCR-ABL1 positive
+4 more
· childhood acute myeloid leukemia · childhood myelodysplastic syndrome · leukemia, myeloid, accelerated-phase · therapy related acute myeloid leukemia and myelodysplastic syndrome
Investigated by: Fred Hutchinson Cancer Center · National Cancer Institute (NCI)

today NCT00052598 · Ph 1/2

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT00052598	Sep 2002 → Nov 2009	acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32) +8	Fred Hutchinson Cancer Center	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	allogeneic CD8+ PR3-specific CTLs	“Patients receive allogeneic CD8+ PR3-specific CTLs intravenously (IV) over 1-2 hours on days 0, 7, 14, 28, and 49” NCT00052598 ↗
Action	Deplete	“may kill more cancer cells” NCT00052598 ↗
Modality	Cell therapy	“donor CD8+ cytotoxic T lymphocytes (CTL) clones” NCT00052598 ↗
Route	Intravenous	“allogeneic CD8+ PR3-specific CTLs intravenously (IV)” NCT00052598 ↗